Literature DB >> 12637334

Role of deferiprone in chelation therapy for transfusional iron overload.

A Victor Hoffbrand1, Alan Cohen, Chaim Hershko.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12637334     DOI： 10.1182/blood-2002-06-1867

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  44 in total

1.  Thyroid function in major thalassemia patients: Is it related to height and chelation therapy?

Authors:  Peiman Eshragi; Ahmad Tamaddoni; Khadijeh Zarifi; Amir Mohammadhasani; Majid Aminzadeh
Journal:  Caspian J Intern Med       Date:  2011

Review 2.  Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.

Authors:  Ellis J Neufeld
Journal:  Blood       Date:  2006-05-01       Impact factor: 22.113

3.  The thalassemias and related disorders.

Authors:  Alain J Marengo-Rowe
Journal:  Proc (Bayl Univ Med Cent)       Date:  2007-01

Review 4.  Guidelines on haemovigilance of post-transfusional iron overload.

Authors:  Angel Remacha; Cristina Sanz; Enric Contreras; Cristina Díaz De Heredia; Joan Ramón Grifols; Montserrat Lozano; Guillermo Martín Nuñez; Ramón Salinas; Mercedes Corral; Ana Villegas
Journal:  Blood Transfus       Date:  2012-07-04       Impact factor: 3.443

5.  Population pharmacokinetics of deferiprone in healthy subjects.

Authors:  Francesco Bellanti; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2014-12       Impact factor: 4.335

Review 6.  Deferasirox for managing iron overload in people with myelodysplastic syndrome.

Authors:  Joerg J Meerpohl; Lisa K Schell; Gerta Rücker; Nigel Fleeman; Edith Motschall; Charlotte M Niemeyer; Dirk Bassler
Journal:  Cochrane Database Syst Rev       Date:  2014-10-28

7.  Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes.

Authors:  S Allegra; J Cusato; S De Francia; A Arduino; F Longo; E Pirro; D Massano; A De Nicolò; A Piga; A D'Avolio
Journal:  Pharmacogenomics J       Date:  2017-11-21       Impact factor: 3.550

8.  Global epidemiology of haemoglobin disorders and derived service indicators.

Authors:  Bernadette Modell; Matthew Darlison
Journal:  Bull World Health Organ       Date:  2008-06       Impact factor: 9.408

9.  Safety and efficacy of iron chelation therapy with deferiprone in patients with transfusion-dependent thalassemia.

Authors:  Saumya S Jamuar; Angeline H M Lai
Journal:  Ther Adv Hematol       Date:  2012-10

10.  Can homeopathy bring additional benefits to thalassemic patients on hydroxyurea therapy? Encouraging results of a preliminary study.

Authors:  Antara Banerjee; Sudipa Basu Chakrabarty; Susanta Roy Karmakar; Amit Chakrabarty; Surjyo Jyoti Biswas; Saiful Haque; Debarsi Das; Saili Paul; Biswapati Mandal; Boujedaini Naoual; Philippe Belon; Anisur Rahman Khuda-Bukhsh
Journal:  Evid Based Complement Alternat Med       Date:  2007-10-29       Impact factor: 2.629
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.